HMGB1 and infection: To date, however, no anti-HMGB1 mAb has entered clinical trials for CNS or other indications, and potential concerns such as immunogenicity, infection risk, interference with reparative HMGB1 functions, and long-term risk-benefit must be carefully addressed, underscoring both the promise and the current translational gap of this strategy.